suramin has been researched along with Lymphoma, Large B-Cell, Diffuse in 3 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " FCE 26644 and suramin, a compound possessing the same terminal half-life (t1/2) in mice and, presumably, the same mode of action, inhibit the growth of solid murine tumors, M5076 reticulosarcoma, and MXT and S180 fibrosarcoma and are inactive against B16F10 melanoma." | 3.69 | Antitumor activity of FCE 26644 a new growth-factor complexing molecule. ( Farao, M; Grandi, M; Marsiglio, A; Mongelli, N; Pesenti, E; Sola, F, 1995) |
| " A dose-response experiment in the B16F10 melanoma model showed that inhibition of lung colony formation was still significant with 50 mg/kg pretreatment, whereas a borderline effect was observed at 10 mg/kg." | 1.29 | Inhibition of lung and liver tumor colonies in mice pretreated with suramin. ( Farao, M; Grandi, M; Mariani, M; Marsiglio, A; Sola, F, 1993) |
| "Suramin was also studied in an in vivo model of tumour-induced angiogenesis using the murine M5076 reticulosarcoma, a tumour producing significant levels of bFGF." | 1.28 | Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. ( Grandi, M; Mongelli, N; Pesenti, E; Sola, F; Spreafico, F, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sola, F | 3 |
| Farao, M | 2 |
| Pesenti, E | 2 |
| Marsiglio, A | 2 |
| Mongelli, N | 2 |
| Grandi, M | 3 |
| Mariani, M | 1 |
| Spreafico, F | 1 |
3 other studies available for suramin and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Antitumor activity of FCE 26644 a new growth-factor complexing molecule.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Distamycins; Drug Administration Schedule; Drug Re | 1995 |
Inhibition of lung and liver tumor colonies in mice pretreated with suramin.
Topics: Animals; Dose-Response Relationship, Drug; Female; Liver Neoplasms; Lung Neoplasms; Lymphoma, Large | 1993 |
Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity.
Topics: Animals; Female; Fibroblast Growth Factor 2; Hemoglobins; Heparin; Lymphoma, Large B-Cell, Diffuse; | 1992 |